Considering that the anti-IgLON5 syndrome usually has a protracted clinical course and is diagnosed many months after symptom onset (in contrast to NMDAR or AMPAR encephalitis which have a rapid presentation in days or weeks), our findings suggest that an early and prompt intervention with immunotherapy may potentially stabilize or decrease the reduction of IgLON5. This evidence concerns the gene IGLON5 and encephalitis.